Vaxcyte (PCVX) Expected to Announce Earnings on Tuesday

Vaxcyte (NASDAQ:PCVX) is projected to post its quarterly earnings results after the market closes on Tuesday, February 25th. Analysts expect Vaxcyte to post earnings of ($1.16) per share for the quarter. Investors that are interested in registering for the company’s earnings conference call can do so using this link.

Vaxcyte Trading Down 3.3 %

NASDAQ:PCVX opened at $79.74 on Friday. Vaxcyte has a 12-month low of $58.10 and a 12-month high of $121.06. The stock has a 50-day moving average price of $85.61 and a 200 day moving average price of $94.76. The stock has a market capitalization of $9.94 billion, a P/E ratio of -17.33 and a beta of 0.98.

Insider Buying and Selling

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total transaction of $710,240.00. Following the transaction, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,720,610.98. This trade represents a 6.81 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Teri Loxam sold 6,250 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now owns 7,175 shares in the company, valued at $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 76,616 shares of company stock valued at $6,766,481. Insiders own 3.10% of the company’s stock.

Analyst Ratings Changes

PCVX has been the subject of a number of research reports. The Goldman Sachs Group assumed coverage on Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Vaxcyte in a research note on Tuesday, February 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $127.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.